# Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine

> **NCT00127855** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 409 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** Hib-MenCY-TT vaccine (MenHibrix)
- **BIOLOGICAL:** Meningitec®
- **BIOLOGICAL:** ActHIB®
- **BIOLOGICAL:** Infanrix® Penta
- **BIOLOGICAL:** Prevenar®
- **BIOLOGICAL:** Mencevax® ACWY
- **BIOLOGICAL:** PRP (Polyribosyl Ribitol Phosphate)

## Key facts

- **NCT ID:** NCT00127855
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-01
- **Primary completion:** 2004-02-01
- **Final completion:** 2004-02-12
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00127855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00127855, "Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00127855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*